Is Enoxaparin registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 36 valid registrations of Enoxaparin, including CLEXANE 20MG\0.2ML PREFILLED SYRINGE (20 mg, Solution for injection, SAR 23.05); CLEXANE 40MG\0.4ML PREFILLED SYRINGE (40 mg, Solution for injection, SAR 39.65); CLEXANE 60MG\0.6ML PREFILLED SYRINGE (60 mg, Solution for injection, SAR 55.30); CLEXANE 80MG\0.8ML PREFILLED SYRINGE (80 mg, Solution for injection, SAR 68.20); Coguperin 20 mg per 0.2 ml (20 mg, Solution for injection, SAR 18.20).

Is Enoxaparin approved by the US FDA?

Drugs@FDA lists 15 application product lines for Enoxaparin, including LOVENOX (PRESERVATIVE FREE) (Prescription); LOVENOX (Prescription); LOVENOX (Prescription); ENOXAPARIN SODIUM (PRESERVATIVE FREE) (Prescription); ENOXAPARIN SODIUM (PRESERVATIVE FREE) (Prescription).

Is Enoxaparin authorised in the European Union?

EMA lists 1 centrally authorised medicine containing Enoxaparin: Inhixa.

Is Enoxaparin on the WHO Model List of Essential Medicines?

Yes — 10.2. Medicines affecting coagulation (core list): Acute ischaemic heart disease; Venous thromboembolism.

Are there safety signals or safety updates for Enoxaparin?

EMA PRAC: 1 entry; US FDA: 1 entry (latest 2023-04-14).

Active substance

Enoxaparin

SFDA 36
US FDA 15
EMA 2
Health Canada 44
US price lines 9
NHS prices 8
WHO EML 1
Safety 2

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
CLEXANE 20MG\0.2ML PREFILLED SYRINGE	20 mg	Solution for injection · Intravenous use	2 Pre-filled syringe	SAR 23.05	Biological · Prescription	Sanofi Aventis France	Valid
CLEXANE 40MG\0.4ML PREFILLED SYRINGE	40 mg	Solution for injection · Intravenous use	2 Pre-filled syringe	SAR 39.65	Biological · Prescription	sanofi-aventis FRANCE	Valid
CLEXANE 60MG\0.6ML PREFILLED SYRINGE	60 mg	Solution for injection · Intravenous use	2 Pre-filled syringe	SAR 55.30	Biological · Prescription	sanofi-aventis	Valid
CLEXANE 80MG\0.8ML PREFILLED SYRINGE	80 mg	Solution for injection · Intravenous use	2 Pre-filled syringe	SAR 68.20	Biological · Prescription	sanofi-aventis	Valid
Coguperin 20 mg per 0.2 ml	20 mg	Solution for injection · Subcutaneous use	2 Pre-filled syringe	SAR 18.20	Biological · Prescription	VENUS REMEDIES LIMITED	Valid
Coguperin 40 mg per 0.4 ml	40 mg	Solution for injection · Subcutaneous use	2 Pre-filled syringe	SAR 28.20	Biological · Prescription	VENUS REMEDIES LIMITED	Valid
Coguperin 60 mg per 0.6 ml	60 mg	Solution for injection · Subcutaneous use	2 Pre-filled syringe	SAR 39.70	Biological · Prescription	VENUS REMEDIES LIMITED	Valid
Coguperin 80 mg per 0.8 ml	80 mg	Solution for injection · Subcutaneous use	2 Pre-filled syringe	SAR 49.30	Biological · Prescription	VENUS REMEDIES LIMITED	Valid
ENDOSA 2000IU PRE-FILLED SYRINGE	20 mg	Solution for injection · Subcutaneous use	2 Pre-filled syringe	SAR 19.60	Biological · Prescription	SPIMACO	Valid
ENDOSA 4000IU PRE-FILLED SYRINGE	40 mg	Solution for injection · Subcutaneous use	2 Pre-filled syringe	SAR 33.80	Biological · Prescription	SPIMACO	Valid
ENDOSA 6000IU PRE-FILLED SYRINGE	60 mg	Solution for injection · Subcutaneous use	2 Pre-filled syringe	SAR 47.00	Biological · Prescription	SPIMACO	Valid
ENDOSA 8000IU PRE-FILLED SYRINGE	80 mg	Solution for injection · Subcutaneous use	2 Pre-filled syringe	SAR 58.00	Biological · Prescription	SPIMACO	Valid
ENOXA	20 mg	Solution for injection · Subcutaneous use	2 Pre-filled syringe	SAR 18.20	Biological · Prescription	LES LABORATOIRES MEDIS	Valid
ENOXA	80 mg	Solution for injection · Subcutaneous use	2 Pre-filled syringe	SAR 49.30	Biological · Prescription	LES LABORATOIRES MEDIS	Valid
ENOXA	60 mg	Solution for injection · Subcutaneous use	2 Pre-filled syringe	SAR 39.70	Biological · Prescription	LES LABORATOIRES MEDIS	Valid
ENOXA	40 mg	Solution for injection · Subcutaneous use	2 Pre-filled syringe	SAR 28.20	Biological · Prescription	LES LABORATOIRES MEDIS	Valid
Enoxaparin BOS	20 mg	Solution for injection · Intravenous use	6 Pre-filled syringe	SAR 41.10	Biological · Prescription	Boston Oncology Arabia	Valid
Enoxaparin BOS	40 mg	Solution for injection · Intravenous use	6 Pre-filled syringe	SAR 70.75	Biological · Prescription	Boston Oncology Arabia	Valid
Enoxaparin BOS	60 mg	Solution for injection · Intravenous use	6 Pre-filled syringe	SAR 98.70	Biological · Prescription	Boston Oncology Arabia	Valid
Enoxaparin BOS	80 mg	Solution for injection · Intravenous use	6 Pre-filled syringe	SAR 121.75	Biological · Prescription	Boston Oncology Arabia	Valid
Enoxaparin BOS	20 mg	Solution for injection · Intravenous use	2 Pre-filled syringe	SAR 13.70	Biological · Prescription	Boston Oncology Arabia	Valid
Enoxaparin BOS	40 mg	Solution for injection · Intravenous use	2 Pre-filled syringe	SAR 23.60	Biological · Prescription	Boston Oncology Arabia	Valid
Enoxaparin BOS	60 mg	Solution for injection · Intravenous use	2 Pre-filled syringe	SAR 32.90	Biological · Prescription	Boston Oncology Arabia	Valid
Enoxaparin BOS	80 mg	Solution for injection · Intravenous use	2 Pre-filled syringe	SAR 40.55	Biological · Prescription	Boston Oncology Arabia	Valid
FARINOX 20MG/0.2ML SOLUTION FOR INJECTION	20 mg	Solution for injection · Intravenous, Subcutaneous	2 Pre-filled syringe	SAR 19.60	Biological · Prescription	MS Pharma Saudi (MSPS)	Valid

11 more — full table

Indications — CHI Daman Drug Formulary

ANTIPHOSPHOLIPID SYNDROME; BURN MANAGEMENT; CARDIOMYOPATHY; MULTIPLE MYELOMA; PORTAL VEIN THROMBOSIS; PULMONARY EMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; VENOUS THROMBOEMBOLISM DISEASE (VTE)-TREATMENT

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
LOVENOX (PRESERVATIVE FREE)	30MG/0.3ML (100MG/ML); 40MG/0.4ML (100MG/ML); 60MG/0.6ML (100MG/ML); 80MG/0.8ML (100MG/ML); 100MG/ML (100MG/ML); 120MG/0.8ML (150MG/ML); 150MG/ML (150MG/ML)	injectable · subcutaneous	SANOFI AVENTIS US	Prescription	29 Mar 1993
LOVENOX	300MG/3ML (100MG/ML)	injectable · intravenous, subcutaneous	SANOFI AVENTIS US	Prescription	29 Mar 1993
LOVENOX	100MG/ML	injectable · injection	SANOFI AVENTIS US	Prescription	16 May 2007
ENOXAPARIN SODIUM (PRESERVATIVE FREE)	100MG/ML (100MG/ML); 30MG/0.3ML (100MG/ML); 40MG/0.4ML (100MG/ML); 60MG/0.6ML (100MG/ML); 80MG/0.8ML (100MG/ML); 120MG/0.8ML (150MG/ML); 150MG/ML (150MG/ML)	injectable · subcutaneous	SANDOZ	Prescription	23 Jul 2010
ENOXAPARIN SODIUM (PRESERVATIVE FREE)	30MG/0.3ML (100MG/ML); 40MG/0.4ML (100MG/ML); 60MG/0.6ML (100MG/ML); 80MG/0.8ML (100MG/ML); 100MG/ML (100MG/ML); 120MG/0.8ML (150MG/ML); 150MG/ML (150MG/ML)	injectable · subcutaneous	AMPHASTAR PHARM	Prescription	19 Sep 2011
ENOXAPARIN SODIUM	300MG/3ML (100MG/ML)	injectable · intravenous, subcutaneous	SANDOZ INC	Prescription	28 Nov 2011
ENOXAPARIN SODIUM (PRESERVATIVE FREE)	30MG/0.3ML (100MG/ML); 40MG/0.4ML (100MG/ML); 60MG/0.6ML (100MG/ML); 80MG/0.8ML (100MG/ML); 100MG/ML (100MG/ML); 120MG/0.8ML (150MG/ML); 150MG/ML (150MG/ML)	injectable · subcutaneous	ZYDUS PHARMS	Prescription	23 Jun 2014
ENOXAPARIN SODIUM (PRESERVATIVE FREE)	30MG/0.3ML (100MG/ML); 40MG/0.4ML (100MG/ML); 60MG/0.6ML (100MG/ML); 80MG/0.8ML (100MG/ML); 100MG/ML (100MG/ML); 120MG/0.8ML (150MG/ML); 150MG/ML (150MG/ML)	injectable · subcutaneous	GLAND	Prescription	28 Sep 2018
ENOXAPARIN SODIUM	300MG/3ML (100MG/ML)	injectable · intravenous, subcutaneous	AMPHASTAR PHARMS INC	Prescription	14 Mar 2019
ENOXAPARIN SODIUM (PRESERVATIVE FREE)	30MG/0.3ML (100MG/ML); 40MG/0.4ML (100MG/ML); 60MG/0.6ML (100MG/ML); 80MG/0.8ML (100MG/ML); 100MG/ML (100MG/ML); 120MG/0.8ML (150MG/ML); 150MG/ML (150MG/ML)	injectable · subcutaneous	EMERGE BIOSCIENCE	Prescription	29 Nov 2019
ENOXAPARIN SODIUM	300MG/3ML (100MG/ML)	injectable · intravenous, subcutaneous	EMERGE BIOSCIENCE	Prescription	14 Jun 2022
ENOXAPARIN SODIUM (PRESERVATIVE FREE)	30MG/0.3ML (100MG/ML); 40MG/0.4ML (100MG/ML); 60MG/0.6ML (100MG/ML); 80MG/0.8ML (100MG/ML); 100MG/ML (100MG/ML); 120MG/0.8ML (150MG/ML); 150MG/ML (150MG/ML)	injectable · subcutaneous	SHENZHEN TECHDOW	Prescription	15 Mar 2023
ENOXAPARIN SODIUM (PRESERVATIVE FREE)	30MG/0.3ML (100MG/ML); 40MG/0.4ML (100MG/ML); 60MG/0.6ML (100MG/ML); 80MG/0.8ML (100MG/ML); 100MG/ML (100MG/ML); 120MG/0.8ML (150MG/ML); 150MG/ML (150MG/ML)	injectable · subcutaneous	BE PHARMS	Prescription	6 Jun 2023
ENOXAPARIN SODIUM (PRESERVATIVE FREE)	30MG/0.3ML (100MG/ML); 40MG/0.4ML (100MG/ML); 60MG/0.6ML (100MG/ML); 80MG/0.8ML (100MG/ML); 100MG/ML (100MG/ML); 120MG/0.8ML (150MG/ML); 150MG/ML (150MG/ML)	injectable · subcutaneous	HEBEI CHANGSHAN	Prescription	7 Jan 2026
LOVENOX (PRESERVATIVE FREE)	90MG/0.6ML (150MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	injectable · subcutaneous	SANOFI AVENTIS US	Discontinued	29 Mar 1993

EMA European Union — centrally authorised medicines

Inhixa Techdow Pharma Netherlands B.V. · Authorised · authorised 15 Sep 2016 · ATC B01AB05

Therapeutic indication (EMA)

Inhixa is indicated for adults for: Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery. Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL). Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism. Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA). Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL). Blood clot prevention in the extracorporeal circulation during haemodialysis.

Thorinane Pharmathen S.A. · Lapsed · authorised 14 Sep 2016 · ATC B01AB05

Therapeutic indication (EMA)

Thorinane is indicated for adults for: - Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery. - Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL). - Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism. - Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA). - Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL). - Blood clot prevention in the extracorporeal circulation during haemodialysis. Prevention and treatment of various disorders related to blood clots in adults.

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
AXBERI	02539977	30 MG / 0.3 ML	SOLUTION · SUBCUTANEOUS; INTRAVENOUS	BAXTER CORPORATION
AXBERI	02539985	40 MG / 0.4 ML	SOLUTION · SUBCUTANEOUS; INTRAVENOUS	BAXTER CORPORATION
AXBERI	02540002	60 MG / 0.6 ML	SOLUTION · SUBCUTANEOUS; INTRAVENOUS	BAXTER CORPORATION
AXBERI	02540010	80 MG / 0.8 ML	SOLUTION · SUBCUTANEOUS; INTRAVENOUS	BAXTER CORPORATION
AXBERI	02540045	100 MG / ML	SOLUTION · INTRAVENOUS; SUBCUTANEOUS	BAXTER CORPORATION
AXBERI HP	02540029	120 MG / 0.8 ML	SOLUTION · INTRAVENOUS; SUBCUTANEOUS	BAXTER CORPORATION
AXBERI HP	02540037	150 MG / ML	SOLUTION · SUBCUTANEOUS; INTRAVENOUS	BAXTER CORPORATION
ELONOX	02532247	30 MG / 0.3 ML	SOLUTION · INTRAVENOUS; SUBCUTANEOUS	FRESENIUS KABI CANADA LTD
ELONOX	02532255	40 MG / 0.4 ML	SOLUTION · INTRAVENOUS; SUBCUTANEOUS	FRESENIUS KABI CANADA LTD
ELONOX	02532263	60 MG / 0.6 ML	SOLUTION · INTRAVENOUS; SUBCUTANEOUS	FRESENIUS KABI CANADA LTD
ELONOX	02532271	80 MG / 0.8 ML	SOLUTION · INTRAVENOUS; SUBCUTANEOUS	FRESENIUS KABI CANADA LTD
ELONOX	02532298	100 MG / ML	SOLUTION · INTRAVENOUS; SUBCUTANEOUS	FRESENIUS KABI CANADA LTD
ELONOX HP	02532301	120 MG / 0.8 ML	SOLUTION · INTRAVENOUS; SUBCUTANEOUS	FRESENIUS KABI CANADA LTD
ELONOX HP	02532328	150 MG / ML	SOLUTION · SUBCUTANEOUS; INTRAVENOUS	FRESENIUS KABI CANADA LTD
INCLUNOX	02507501	30 MG / 0.3 ML	SOLUTION · INTRAVENOUS; SUBCUTANEOUS	SANDOZ CANADA INCORPORATED
INCLUNOX	02507528	40 MG / 0.4 ML	SOLUTION · INTRAVENOUS; SUBCUTANEOUS	SANDOZ CANADA INCORPORATED
INCLUNOX	02507536	60 MG / 0.6 ML	SOLUTION · SUBCUTANEOUS; INTRAVENOUS	SANDOZ CANADA INCORPORATED
INCLUNOX	02507544	80 MG / 0.8 ML	SOLUTION · INTRAVENOUS; SUBCUTANEOUS	SANDOZ CANADA INCORPORATED
INCLUNOX	02507552	100 MG / 1 ML	SOLUTION · SUBCUTANEOUS; INTRAVENOUS	SANDOZ CANADA INCORPORATED
INCLUNOX HP	02507560	120 MG / 0.8 ML	SOLUTION · SUBCUTANEOUS; INTRAVENOUS	SANDOZ CANADA INCORPORATED
INCLUNOX HP	02507579	150 MG / 1 ML	SOLUTION · INTRAVENOUS; SUBCUTANEOUS	SANDOZ CANADA INCORPORATED
LOVENOX	02012472	30 MG / 0.3 ML	SOLUTION · SUBCUTANEOUS	SANOFI-AVENTIS CANADA INC
LOVENOX	02236883	40 MG / 0.4 ML	SOLUTION · SUBCUTANEOUS	SANOFI-AVENTIS CANADA INC
LOVENOX	02378426	60 MG / 0.6 ML	SOLUTION · SUBCUTANEOUS	SANOFI-AVENTIS CANADA INC
LOVENOX	02378434	80 MG / 0.8 ML	SOLUTION · SUBCUTANEOUS	SANOFI-AVENTIS CANADA INC

19 more — full table

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
US NADAC	ENOXAPARIN 100 MG/ML SYRINGE	$6.45169	per ML	23 Sep 2026
US NADAC	ENOXAPARIN 120 MG/0.8 ML SYR	$10.41734	per ML	23 Sep 2026
US NADAC	ENOXAPARIN 150 MG/ML SYRINGE	$8.90376	per ML	23 Sep 2026
US NADAC	ENOXAPARIN 30 MG/0.3 ML SYR	$9.12683	per ML	23 Sep 2026
US NADAC	ENOXAPARIN 300 MG/3 ML VIAL	$9.87241	per ML	23 Sep 2026
US NADAC	ENOXAPARIN 40 MG/0.4 ML SYR	$7.7791	per ML	23 Sep 2026
US NADAC	ENOXAPARIN 60 MG/0.6 ML SYR	$7.45223	per ML	23 Sep 2026
US NADAC	ENOXAPARIN 80 MG/0.8 ML SYR	$6.68676	per ML	23 Sep 2026
US NADAC	LOVENOX 40 MG/0.4 ML SYRINGE	$6.775	per ML	19 Nov 2025
NHS Drug Tariff	Enoxaparin sodium 100mg/1ml solution for injection pre-filled syringes	£72.30	10 pre-filled disposable injection	1 Oct 2026
NHS Drug Tariff	Enoxaparin sodium 120mg/0.8ml solution for injection pre-filled syringes	£87.93	10 pre-filled disposable injection	1 Oct 2026
NHS Drug Tariff	Enoxaparin sodium 150mg/1ml solution for injection pre-filled syringes	£99.91	10 pre-filled disposable injection	1 Oct 2026
NHS Drug Tariff	Enoxaparin sodium 20mg/0.2ml solution for injection pre-filled syringes	£20.86	10 pre-filled disposable injection	1 Oct 2026
NHS Drug Tariff	Enoxaparin sodium 300mg/3ml solution for injection vials	£21.33	1 vial	1 Oct 2026
NHS Drug Tariff	Enoxaparin sodium 40mg/0.4ml solution for injection pre-filled syringes	£30.27	10 pre-filled disposable injection	1 Oct 2026
NHS Drug Tariff	Enoxaparin sodium 60mg/0.6ml solution for injection pre-filled syringes	£39.26	10 pre-filled disposable injection	1 Oct 2026
NHS Drug Tariff	Enoxaparin sodium 80mg/0.8ml solution for injection pre-filled syringes	£55.13	10 pre-filled disposable injection	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

WHO WHO Model List of Essential Medicines (2025)

10.2. Medicines affecting coagulation · core
Acute ischaemic heart disease; Venous thromboembolism
Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

Safety signals and safety-related labeling changes

EMA PRAC 14 Apr 2023 PRAC signal: Angiokeratoma
Action for MAH: update of the product information: No
US FDA 11 Dec 2018 LOVENOX — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide

All safety entries for enoxaparin →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.